Replies to post #388214 on Elite Pharmaceuticals Inc (ELTP)

[mrwrn2010]

Yep the “worst case” scenarios here regarding Vyvanse still have us sitting pretty.

This is excluding Oxy and if Concerta is indeed the 3rd needle mover product.

Add the 2 smaller drugs we should get approval for within the next 4 months or so.

Vigabatrin with Pyros.

Prasco/Burel on Jan 1.

Dexcel wildcard.

Whatever else we don’t know about yet in earlier pipeline stages.